Categories: News

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that it plans to host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10157874. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

Staff

Recent Posts

Avosina Healthcare Solutions Provides Notice of Data Incident

LORTON, Va., Jan. 9, 2026 /PRNewswire/ -- Avosina Healthcare Solutions ("Avosina") is notifying individuals of…

27 minutes ago

SimpleC joins Digital Medicine Society (DiMe) at CES, announces new AI-powered companion for family caregivers

Caregiver companion, named Wellby, provides 24/7 emotional support and guidance as part of SimpleC's Connected…

27 minutes ago

Prescryptive and Ilant Health Expand Employer-Direct Access to Obesity Care and Transparent GLP-1 Access at Scale

REDMOND, Wash., Jan. 9, 2026 /PRNewswire/ -- Prescryptive and Ilant Health today announced a collaboration…

27 minutes ago

Brado and Santé Ventures Partner to Transform Patient Navigation and Engagement

Investment spurs creation of Brado AI, a dedicated technology entity focused on extending provider reach…

27 minutes ago

Strategic Healthcare AI Asset “HealthcareAI.com” Positioned as Cornerstone for the Rapidly Evolving Medical Technology Sector

BILLINGS, Mont., Jan. 9, 2026 /PRNewswire/ -- As the convergence of medicine and artificial intelligence…

27 minutes ago